Inflammation and genitourinary cancers are tightly connected, and numerous inflammatory pathways, including the vascular endothelial growth factor (VEGF), von Hippel-Lindau (VHL), the mechanistic target of rapamycin (mTOR), TNF and STAT signaling cascade, are involved. Here, VEGFA is linked to urogenital neoplasm.